Genetic Testing at AdventHealth Alerts Woman, Doctors to Aggressive Cancer Before it Develops
A genetic test, originally conducted to help better understand her daughter's diagnosis, revealed Samantha Arceneaux carries a genetic variant that virtually guarantees she will develop an aggressive...
AdventHealth Clinical Research Unit Recruiting Patients with Solid Tumors Harboring MTAP Deletion for Phase I Clinical Trial
Under the leadership of investigator Guru Sonpavde, MD, AdventHealth’s Clinical Research Unit (CRU), a collaborative between the AdventHealth Cancer Institute and AdventHealth Research Institute, is...
Global article with tags and multiple facility assignments
Once you’ve had a heart attack, you’re at increased risk for another. AdventHealth shares ways to protect your heart, so you can avoid another cardiac event.
AdventHealth Research Institute conducting two studies on the impact of shift work on healthcare workers’ health
The AdventHealth Research Institute recently launched two new clinical studies to better understand and address the needs of healthcare employees who work night shifts.
AdventHealth Celebration Successfully Performs First Robotics-assisted Cochlear Implant Procedure in Florida with the iotaSOFT® Insertion System.
In January 2024, AdventHealth Celebration neurotologist Michael Seidman, MD, FACS, became the first in Florida and the Southeast to complete a robotics-assisted cochlear implant procedure using the...
New Implantable Heart Attack Detection and Warning System Advances Care for High-risk Acute Coronary Syndrome Patients
Avertix’s Guardian™ System, the first and only implantable device approved by the U.S. Food and Drug Administration (FDA) for use in patients who have had prior acute coronary syndrome (ACS) events...
New England Journal of Medicine highlights Guru Sonpavde, MD’s work in new immunotherapy-chemotherapy combination improving survival for patients with advanced urothelial carcinoma
The CheckMate 901 Phase III clinical trial results, recently published in the New England Journal of Medicine, found that combining the programmed death 1 (PD1) inhibitor immunotherapy nivolumab with...
Our website uses cookies. Please review our privacy policy to find out more about the cookies we use. Browsing our website means you accept these terms.